The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis

被引:3
作者
Quesada, Jose A. [1 ,2 ]
Bertomeu-Gonzalez, Vicente [1 ,3 ,4 ]
Orozco-Beltran, Domingo [1 ,2 ]
Cordero, Alberto [3 ,4 ]
Gil-Guillen, Vicente F. [1 ,2 ]
Lopez-Pineda, Adriana [1 ,2 ]
Nouni-Garcia, Rauf [1 ,2 ]
Carratala-Munuera, Concepcion [1 ,2 ]
机构
[1] Miguel Hernandez de Elche Univ, Dept Clin Med, San Juan Campus,332,Km 87, Alicante 03550, Spain
[2] Miguel Hernandez Univ, Chair Primary Care, San Juan de Alicante,322,Km 87, Alicante 03550, Spain
[3] San Juan de Alicante Univ Hosp, Cardiol Sect, San Juan de Alicante 322, Alicante, Spain
[4] Biomed Res Ctr Cardiovasc Dis Network CIBERCV CB16, Av Monforte de Lemos,3-5,Pabellon 11,Planta 0, Madrid 28029, Spain
来源
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS | 2023年 / 35卷 / 04期
关键词
Cardiovascular disease; Cholesterol; Lipoproteins LDL; Lipoproteins HDL; Magnetic resonance spectroscopy; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; CAROTID ATHEROSCLEROSIS; INTERVENTION TRIAL; ARTERY-DISEASE; CHOLESTEROL; HDL; EVENTS; SUBFRACTIONS; PROGRESSION;
D O I
10.1016/j.arteri.2022.11.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: Cardiovascular risk (CVR) is conventionally calculated by measuring the total cholesterol content of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The purpose of this systematic review was to assess the CVR associated with LDL and HDL particle size and number as determined by nuclear magnetic resonance (NMR) spectroscopy.Material and methods: A literature search was performed using the electronic databases MED-LINE and Scopus. All cohort and case--control studies published before January 1, 2019 that met the following inclusion criteria were included: HDL-P, LDL-P, HDL-Z and/or LDL-Z measured by NMR spectroscopy; cardiovascular event as an outcome variable; risk of cardiovascular events expressed as odds ratios or hazard ratios; only adult patients. A meta-analysis was performed for each exposure variable (4 for LDL and 5 for HDL) and for each exposure measure (highest versus lowest quartile and 1-standard deviation increment).Results: This review included 24 studies. Number of LDL particles was directly associated with CVR: risk increased by 28% with each standard deviation increment. LDL particle size was inversely and significantly associated with CVR: each standard deviation increment corresponded to an 8% risk reduction. CVR increased by 12% with each standard deviation increase in number of small LDL particles. HD, particle number and size were inversely associated with CVR. Conclusion: Larger particle size provided greater protection, although this relationship was inconsistent between studies. Larger number of LDL particles and smaller LDL particle size are associated with increased CVR. Risk decreases with increasing number and size of HDL particles.& COPY; 2022 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:165 / 177
页数:13
相关论文
共 51 条
  • [21] Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
    Khera, Amit V.
    Demler, Olga V.
    Adelman, Steven J.
    Collins, Heidi L.
    Glynn, Robert J.
    Ridker, Paul M.
    Rader, Daniel J.
    Mora, Samia
    [J]. CIRCULATION, 2017, 135 (25) : 2494 - +
  • [22] NMR-Based Lipidomic Analysis of Blood Lipoproteins Differentiates the Progression of Coronary Heart Disease
    Kostara, Christina E.
    Papathanasiou, Athanasios
    Psychogios, Nikolaos
    Manh Thong Cung
    Elisaf, Moses S.
    Goudevenos, John
    Bairaktari, Eleni T.
    [J]. JOURNAL OF PROTEOME RESEARCH, 2014, 13 (05) : 2585 - 2598
  • [23] Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome
    Kuller, Lewis H.
    Grandits, Gregory
    Cohen, Jerome D.
    Neaton, James D.
    Prineas, Ronald
    [J]. ATHEROSCLEROSIS, 2007, 195 (01) : 122 - 128
  • [24] Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
    Landray, Martin J.
    Haynes, Richard
    Hopewell, Jemma C.
    Parish, Sarah
    Aung, Theingi
    Tomson, Joseph
    Wallendszus, Karl
    Craig, Martin
    Jiang, Lixin
    Collins, Rory
    Armitage, Jane
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 203 - 212
  • [25] Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol
    Lawler, Patrick R.
    Akinkuolie, Akintunde O.
    Chu, Audrey Y.
    Shah, Svati H.
    Kraus, William E.
    Craig, Damian
    Padmanabhan, Latha
    Glynn, Robert J.
    Ridker, Paul M.
    Chasman, Daniel I.
    Mora, Samia
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (07):
  • [26] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
    Lincoff, A. Michael
    Nicholls, Stephen J.
    Riesmeyer, Jeffrey S.
    Barter, Philip J.
    Brewer, H. Bryan
    Fox, Keith A. A.
    Gibson, C. Michael
    Granger, Christopher
    Menon, Venu
    Montalescot, Gilles
    Rader, Daniel
    Tall, Alan R.
    McErlean, Ellen
    Wolski, Kathy
    Ruotolo, Giacomo
    Vangerow, Burkhard
    Weerakkody, Govinda
    Goodman, Shaun G.
    Conde, Diego
    McGuire, Darren K.
    Nicolau, Jose C.
    Leiva-Pons, Jose L.
    Pesant, Yves
    Li, Weimin
    Kandath, David
    Kouz, Simon
    Tahirkheli, Naeem
    Mason, Denise
    Nissen, Steven E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20) : 1933 - 1942
  • [27] High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events MESA (Multi-Ethnic Study of Atherosclerosis)
    Mackey, Rachel H.
    Greenland, Philip
    Goff, David C., Jr.
    Lloyd-Jones, Donald
    Sibley, Christopher T.
    Mora, Samia
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (06) : 508 - 516
  • [28] HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative
    Martin, Seth S.
    Khokhar, Arif A.
    May, Heidi T.
    Kulkarni, Krishnaji R.
    Blaha, Michael J.
    Joshi, Parag H.
    Toth, Peter P.
    Muhlestein, Joseph B.
    Anderson, Jeffrey L.
    Knight, Stacey
    Li, Yan
    Spertus, John A.
    Jones, Steven R.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (01) : 22 - 30
  • [29] High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort
    McGarrah, Robert W.
    Craig, Damian M.
    Haynes, Carol
    Dowdy, Z. Elaine
    Shah, Svati H.
    Kraus, William E.
    [J]. ATHEROSCLEROSIS, 2016, 246 : 229 - 235
  • [30] Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
    Mora, Samia
    Caulfield, Michael P.
    Wohlgemuth, Jay
    Chen, Zhihong
    Superko, H. Robert
    Rowland, Charles M.
    Glynn, Robert J.
    Ridker, Paul M.
    Krauss, Ronald M.
    [J]. CIRCULATION, 2015, 132 (23) : 2220 - 2229